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Summary
Interleukin 8 (L8), a potent activator ofneutrophils, may be important in the early host response
to serious Gram-negative infections . IL8 was measured with other acute phase cytokines (tumor
necrosis factor a [TNF-a], IL6, and 1140) in 25 normal humans randomized to receive either
intravenous endotoxin alone or endotoxin after oral administration ofibuprofen or pentoxifylline,
agents that alter some of the inflammatory responses induced by endotoxin in vitro . TNF
immunoreactivity was maximum at 1.5 h, and total TNF (area under the curve) was 4.2- and
4.5-fold greater in subjects given endotoxin/ibuprofen compared to subjects given endotoxin
alone (p = 0.026) or endotoxin/pentoxifylhne (p = 0.004), respectively. IL6 levels weremaximum
at 2-3 h and did not differ among the three groups . No 1110 was detected in any subject . IL8
levels peaked at 2 h in subjects given either endotoxin alone or endotoxin/pentoxifylline, falling
towards baseline by 5 h . Subjects given endotoxin/ibuprofen had a more sustained rise in IL8
with peak levels 2.8- and 2.5-fold higher at 3 h compared to endotoxin alone (p = 0.048) or
endotoxin/pentoxifylline (p = 0.023), respectively. Differences in total IL8 releaseamong groups
approached statistical significance (ANOVA, p = 0.07) . This trend reflected the increased release
of 11,8 by the subjects receiving ibuprofen compared to pentoxifylline (1.9-fold higher ; p =
0.024) . This suggests that cyclooxygenase products may provide important negative feedback
loops for cytokine production in vivo. Increases in circulating IL-8 are part of the acute inflammatory
response of humans to endotoxin . Altered cytokine responses caused by antiinflammatory therapy
may have important implications for both host defense and injury during septicemia .
E
ndotoxin activates a variety of host inflammatory responses
and plays a role in septic shock and multiple organ failure
(1) . A model based on the administration of endotoxin to
normal humans qualitatively reproduces several features of
host responses which are similar to those occurring during
the early stages of bacterial infection (2-4) . After stimula-
tion by endotoxin, IL8 is expressed by several cell types, in-
cluding monocyte/macrophages and endothelial cells . Neu-
trophil exposure to 11,8 in vitro results in proinflammatory
effects, including neutrophil chemotaxis, degranulation, and
expression of cell surface markers (5) . We measured the re-
lease of IL-8 and its relationship to TNF-a, IL-10, and Ilr6
release after administration of endotoxin to normal humans.
Additionally, the roles of two antiinflammatory agents,
ibuprofen or pentoxifylline, on this acute response were evalu-
ated. In animal and in vitro studies both of these agents have
andinflammatory and cytokine-modulating effects that sug-
gest that they may be therapeutically beneficial in septic shock
(6-9) .
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Materials and Methods
Subjects.
￿
25 healthy volunteers (20 men, 5 women ; 18-40 y
old, mean 28 yr) were evaluated . The protocol was approved by
our institutional review board and written consent was obtained
from all subjects . The current investigation was performed simul-
taneously with evaluation of the effects of endotoxin and an-
tiinflammatory agents on cardiovascular function (10) . U.S . Stan-
dard Reference Endotoxin (Lot EC-5, Escherichia coli 0113, Food
and Drug Administration) was administered intravenously (4 ng/kg
of body wt) over 1 min and flushed with 10 ml of normal saline.
Subjects were randomized into three groups : (a) no treatment be-
fore endotoxin (n = 6), (b) oral ibuprofen (Upjohn, Kalamazoo,
MI) 800 mg 1.5 h before, at the time of, and 3 h after endotoxin
(n = 9), and (c) oral pentoxifylline (Hoechst-Roussel, Somerville,
NJ) 400 mg extended release tablets every 8 h for five doses before
endotoxin (n = 10) . Ibuprofen has antipyrogenic effects and alters
some of the acute stress hormone responses after endotoxin ad-
ministration to humans (2) . The pentoxifyllne dosing was chosen
to achieve steady-state therapeutic drug levels during the first 4 h
of the study . After an 8-h fast, the subjects were monitored as pre-
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1021-1024viously described (3). Arterial blood samples were clotted on ice,
centrifuged for 10 min (500 g), and the serum was frozen at - 70°C.
Ibuprofen (Pharmakinetics Laboratory, Baltimore, MD) and pen-
toxifylline (Dr. M. Amantea, Pharmacy Development Service, Na-
tional InstitutesofHealth, Bethesda, MD) plasma levels were mea-
sured using HPLC.
Cytokine Assays.
￿
Serum TNF-at, 1140, and IIr6 were measured
in duplicate using double ligand immunoassays (R & D Systems,
Minneapolis, MN). The limits of detection of these ELISAs were
31 pg/mlfor IL10, and 15 pg/ml for 11,6 and TNF-a . Augmented
TNF immunoreactivity seen in endotoxin/ibuprofen subjects was
further evaluated in all three groups using a cytotoxicity assay
(WEHI 164) (3). IL8 was measured in heat-inactivated serum (56°C
for 30 min) using a double ligand immunoassay (Sandoz Research
Institute, Vienna, Austria) based on a mouse monoclonalanti-IL8
and goat polyclonal anti-IIA linked to alkaline phosphatase. These
antibodies react with endothelial and monocyte-derived 11r8 and
had no measurable crossreactivity with high levels ofother known
cytokines or growth factors (11). The limits of detection were 20
pg/ml of rIIr8.
Statistical Analysis.
￿
Summary statistics are expressed as mean
± SEM. One-way ANOVA and unpaired t tests were used to assess
differences among groups in both the total and temporal cytokine
release. Totalcytokine production was measured by calculating the
area under the curve for each cytokine (12). Correlations were made
using Pearson's r test. Nominal two-tailedp values are reported for
each analysis.
Results
Systemic Responses.
￿
The subjects given endotoxin alone
or endotoxin/pentoxifylline developed feverand constitutional
symptoms (chills, myalgias, headache, and nausea) at 1 h that
were diminished by 5 h. At 3 h, core temperature peaked
from baseline (36.7 ± 0.07°C; all groups) in subjects given
endotoxin (39.1 ± 0.15°C) or endotoxin/pentoxifylline (38.6
± 0.17° C) and approached baseline by 5 h. The symptoms
and the feverwere attenuated by ibuprofen with a maximum
temperature at 3 h (37.3 ± 0.17°C), which was less than
subjects receiving endotoxin alone (p < 0.001) or endo-
toxin/pentoxifylline (p < 0.001). Pentoxifylline plasma levels
at 0, 1.5, and 4 h were 403 ± 97, 257 ± 54, and 281 ±
77 pg/ml, respectively. Ibuprofen levels at 0, 1.5, and 3 h
were 12.2 ± 4.0, 64.5 ± 21.5, and 38.9 ± 12.9 wg/ml, respec-
tively. The total granulocyte count in all 25 subjects decreased
from baseline (3,781 ± 219 x 109/L), to a nadir at 1 h
(1,156 ± 82 x 109/L), rising by 6 h to 9,722 ± 822 x 109/
liter granulocytes and approached baseline values by 24 h (6,897
± 537 x 109/L). Neither ibuprofen nor pentoxifylline al-
tered this response.
Cytokine Measurements.
￿
No TNF was detected in any sub-
ject at 0 h using either the immunoassay or cytotoxicity assay.
The mean TNF immunoreactivity was maximum at 1.5 h
in all three groups (endotoxin alone 812 ± 331, endo-
toxin/pentoxifylline 780 ± 247, endotoxin/ibuprofen 3,194
± 1,065 pg/ml, Fig. 1 A). Total TNF immunoreactivity was
4.2-fold higher in subjects given endotoxin/ibuprofen (4,868
± 1,721 pg/ml) compared to endotoxin alone (1,152 ± 470
pg/ml; p = 0.026) and 4.5-fold higher than subjects given
endotoxin/pentoxifylline (1,077 ± 341 pg/ml; p = 0.004).
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Figure 1 .
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Cytokine response. Alterations in circulating immunoreac-
tive TNF (A), IL6 (B), and 11,8 (C) in normal humans givenintravenous
endotoxin alone, or given endotoxin after oral ibuprofen or oral pentox-
ifylline.
No difference in total TNF release occurred in subjects given
endotoxin/pentoxifylline compared to subjects given endo-
toxin alone. Analysis of TNF cytotoxicity revealed a similar
pattern of TNF release in all three groups. Total TNF cyto-
toxicity was higher in the endotoxin/ibuprofen subjects (1,636
± 578 pg/ml) compared with the endotoxin group (582 ±
237 pg/ml; p = 0.057) or the endotoxin/pentoxifylline group
(369 ± 123 pg/ml; p = 0.017).
No IL -6 was detected in any subject at 0 h. IL6 levels weremaximum at 2 h in the endotoxin group (1,026 ± 250 pg/ml)
and 3 h in the endotoxin/pentoxifylline group (1,009 ± 632
pg/ml) and endotoxin/ibuprofen group (3,176 ± 2,115 pg/ml)
(Fig. 1 B). Total 11,6 response did not differ significantly among
the three groups (endotoxin alone, 2,476 ± 1,107; endo-
toxin/ibuprofen, 11,292 ± 3,992; and endotoxin/pentoxifyl-
line, 2,362 ± 835 pg/ml). No II,1j3 was detected at any time
point.
4 or 25 subjects had detectable 11,8 levels at 0 h (26-46
pg/ml). IL8 levels were maximum at 2 h after endotoxin
alone (641 ± 220 pg/ml) or after endotoxin/pentoxifylline
(633 ± 196 pg/ml) and fell toward baseline values by 3 h
in both groups. Levels of IL8 continued to rise at 2 h in the
endotoxin/ibuprofen group and peaked at 3 h (928 ± 213
pg/ml) (Fig. 1 C). Total 11,8 released was marginally different
among the three groups (ANOVA, p = 0.07), with greater
total 11,8 release after endotoxin/ibuprofen (2,671 ± 890
pg/ml) than endotoxin/pentoxifylline (1,409 ± 470 pg/ml;
p = 0.024) . II,8 levels were higher at 3 and 5 h in the sub-
jects given endotoxin/ibuprofen compared to endotoxin alone
(3 h: p = 0.048; 5 h; p = 0.027) or endotoxin/pentoxifyl-
line (3 h: p = 0.023; 5 h: p = 0.006). Total IL-8 after endo-
toxin alone (1,536 ± 627 pg/ml) was 1.7-fold lower than
the endotoxin/ibuprofen group (p = 0.10) and did not differ
from total IL8 after endotoxin/pentoxifylline.
Total TNF immunoactivity correlated with totalTNF cy-
totoxicity (r = 0.599, p = 0.002), total 11,6 (r = 0.787,
p < 0.001), and total II,8 (r = 0.512, p = 0.009). Total II,6
correlated poorly with IL8 activity (r = 0.278, p = 0.178).
Discussion
11,8 has several properties that suggest that it plays a role
in mediating some ofthe inflammatory responses of neutro-
phils induced by endotoxin, IL1, and TNF (5). In addition
to these proinflammatory responses, endothelial-derived II,8
can inhibit neutrophil adhesion to 11,1-activated endothelial
cells possibly limiting inflammatory damage from neutrophil-
endothelial cell interaction (13). Our studydemonstrates that
11,8 is part of the acute inflammatory response occurring in
humans after the intravenous administration of endotoxin.
11,8 circulates in the blood and maximum levels occur after
an earlier rise in TNF activity, parallel a similar rise in II,6
activity, and then approach baseline values by 6 h. The peak
levels of IL8 after intravenous endotoxin are approximately
fivefold less than those described in patients with septic shock
(14). Thus, the nature, intensity, and duration of the primary
stimulus for IL8 production (i.e., bolus intravenous endo-
toxin vs. persistent bacteremia) may affect the absolute levels
seen during the acute response.
In vitro data suggest that cyclooxygenase products serve
an important function as part of an inhibitory feedback loop
that limits TNF and other cytokine production (9, 15). The
current study demonstrates that cyclooxygenase inhibitors in
vivo result in an augmented release of TNF and IL8. The
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implications of enhanced cytokine release in humans afteren-
dotoxin/ibuprofen remain to be clarified. Animal studies of
septic shock using ibuprofen as a therapeutic adjunct show
improvement in hemodynamic parameters and mortality, yet
rytokine responses have not been reported (8). Additionally,
the use of cyclooxygenase inhibitors can attenuate hypoten-
sion and death in animals given TNF (16, 17). Although TNF
appears to be an important cause of organ damage and mor-
tality in sepsis, a protective role of TNF in the normal host
response to infection has been shown in mice challenged with
live bacteria (18, 19). TNF levels measured by the cytotox-
icity assay in the endotoxin/ibuprofen group are comparable
to those reported during meningococcemia (20). The rela-
tively brief exposure to high TNF levels and the absence of
infection may explain why these levels of TNF were well toler-
ated in our subjects. Alternatively, cyclooxygenase inhibition
may prevent the release of other mediators by TNF and thereby
reduce morbidity despite higher TNF levels.
The levels of TNF after endotoxin/ibuprofen obtained in
our studyare higher than those reported by others using this
model; variation in sample size and TNF assays may account
for these differences (2). However, a recent report confirms
an enhanced release of TNF in humans given ibuprofen and
endotoxin (21). No IL1O was detected in our human sub-
jects after endotoxin administration. 11,10 has not been uni-
formly detected by others after endotoxin administration to
humans, suggestingis serves as a local rather than circulating
mediator of endotoxin-induced inflammatory responses (2,
21, 22) .
Pentoxifylline inhibits TNF message transcription and trans-
lation in vitro (23) . A concentration of 10 -6 to 10-5 M
results in 45-60% suppression of LPS-stimulated monocyte
TNF mRNA (7). The plasma concentration of pentoxifyl-
line in our study ranged from 10 -6 to 10-7M. This level
of drug did not result in a significant diminution of any of
the acute cytokine responses nor were the endotoxin-induced
symptoms altered by the use of pentoxifylline. In contrast,
patients with malignancies receiving oral pentoxifylline had
decreased TNF mRNA in isolated mononuclear cells com-
pared to pretreatment samples and this was associated with
an increased sense of well being (24). Intravenous pentox-
ifylline given to humans before intravenous endotoxin from
Salmonella abortis equii blocked the rise in circulating TNF
(25) . Thus, higher blood levels of pentoxifylline as well as
the nature of the inflammatory stimulus may be integral to
inhibition of the TNF response by pentoxifylline in vivo.
This human model ofibuprofen-enhanced cytokine release
demonstrates that cyclooxygenase products serve as an im-
portant control mechanism that limits 11,8 and TNF release
in vivo. The use of antiinflammatory agents during therapy
of septic shock may result in altered rytokine responses, but
whether manipulation ofthese responses will be detrimental
or useful in the host response to infection needs further in-
vestigation.The authors gratefully acknowledge the statistical analysis provided by Dr. Robert A. Wesley, the tech-
nical assistance ofElizabeth Patterson andJennifer Zablotny, andthecare provided for the normal volun-
teers by Deborah Goslin, R. N., and the Critical Care nurses and therapists of the Clinical Center.
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